演講嘉賓
Filter by:
Jitin Bajaj, Senior Director, Alliance Management, Beam Therapeutics
Jitin Bajaj joined Beam as a Senior Director, Corporate Development in 2021. At Beam, he is focused on business development activities and management of Beam's strategic alliances. Prior to joining Beam, Jitin worked at Merck for 12 years in various technology and business roles. During his time at Merck, he spent several years as an expat providing strategic and operational leadership for some of Merck's key international partnerships. Jitin holds an MBA from Columbia University and a Masters in Science & Engineering from University of Pennsylvania.
Christopher Black, Head, Corporate Alliance Management & Integration, Merck & Co., Inc.
Chris leads Merck Sharp & Dohme’s Corporate Alliance Management & Integration team. This group provides enterprise-level leadership for a multi-billion-dollar portfolio of strategic alliances and collaborations, as well as managing all M&A integration activities. The majority of Chris's 18+ years at Merck have involved management of partnerships for co-development, co-manufacturing, and/or co-commercialization of vaccines, oncology, and other pharmaceutical products. He has managed global, regional, and local strategic alliances, Joint Ventures, and Institutional Business and NGO partnerships collectively active in over 110 countries. Chris participated in the creation of two new multinational biopharma companies, as well as the split-up of a European vaccines company and the spinoff of Organon from Merck. Prior to joining Merck, Chris was an active-duty US Army officer. After military service, Chris joined Cintas Corporation, a business services company, where he held positions including Sales Manager, Plant Manager, Regional Director, and General Manager.
Karen Coffman, Director Alliance Management, Oncology Business Development & Licensing, AstraZeneca
Karen is a Director of Oncology R&D Alliance Management at AstraZeneca, where she has successfully managed global corporate partnerships for AZ's portfolio assets over the past eight years. Her expertise includes leading cross-functional transition teams for mergers and acquisitions, as well as launching and managing a diverse array of strategic partnerships across multiple therapeutic areas within research and clinical development stages. With over 20 years of experience in the biopharmaceutical industry, Karen previously worked as an Oncology Scientist at MedImmune, the former biologics division of AstraZeneca, before moving into her current role in alliance management. She holds a Master of Science in Clinical Sciences from Purdue University and is a certified Project Management Professional (PMP) and Certified Alliance Manager (CA-AM).
Kathy Galle, Executive Director, Alliance Management, GSK
Working in the biotech/pharma sector over the last 20 years, my career has evolved from technical roles in the lab to operational and program leadership, finally finding my perfect niche in alliance management. I've worked at a number of start-up and smaller biotech companies including Codon Devices, RainDance Technologies, Trek Therapeutics, and TESARO, as well as roles in pharma including Vertex, Genzyme, and GSK. I've been at GSK for 5 years and have enjoyed the experience to work on a wide range of partnerships and expand my team in the Boston area.
Andi Gardner, Senior Director, Alliance Management, Biogen
Andi is a business-savvy people person executive with 15+ years of alliance management experience and proven abilities in leadership and global expansion in biotech, pharma, and life sciences. She is multilingual and experienced in managing geographically diverse partners (Asia, Europe, the Americas, and the Middle East). Peer influencer who skillfully negotiates contract terms and operationalizes contracts that represent cross-functional interests within organizations, and who is talented in translating analytical insights into succinct, actionable strategies. At Biogen, she implements, manages, and optimizes complex multiprogram alliances globally. Among others, she previously served as a member of an integration team for Lilly’s acquisition of Dermira and held other alliance management positions at Jazz Pharmaceuticals and Color, as well as in other roles at Amgen, Lonza, and Cambrex. Andi has a great interest in collaboration and partnership, she is a pharmacist by training and holds an MBA from Pepperdine University.
Adam Hammer, Director, Alliance Management, AbCellera
Adam Hammer is an accomplished Alliance Management professional with extensive experience in the biopharmaceutical industry. He began his career in sales within the Boston and San Francisco biotech ecosystems before transitioning into business development for therapeutic antibodies at AbCellera Biologics. Currently serving as Director of Alliance Management, Adam oversees complex co-discovery, co-development, and joint venture alliances. He holds a PhD in Cell Biology, Neurobiology, and Anatomy from Loyola University Chicago. Adam is passionate about fostering cross-functional collaboration, mentorship, and advancing novel biologic medicines to patients through partnerships. Outside of work, Adam enjoys running, traveling, and spending time with his wife and two children.
Brent Harvey, Executive Director, Alliance Management and M&A Integration, Eli Lilly & Co.
Brent leads teams focused on maximizing the value of partnered assets at each stage of the development and commercialization cycle. Brent has played an integral role in some of the largest development and commercial alliances at Lilly, including worldwide partnerships with BMS, Merck KGaA, Daiichi-Sankyo, Innovent Biologics, GSK, and Sanofi. He is also the alliance manager on collaborations with venture capitalists, strategic equity investment companies, and oncology clinical trial collaborations. Brent has responsibilities for M&A integration as well. Brent has an engineering degree from Purdue and an MBA from Indiana University. He also has a CA-AM and is a certified management accountant (CMA).
Katherine Kendrick, Head of Alliance Management, Jazz Pharmaceuticals
Katherine Kendrick is the Executive Director and Head of Alliance Management at Jazz Pharmaceuticals, a global biopharmaceutical company that develops life-changing medicines for people with serious diseases, who often have limited or no options. Katherine leads the Jazz Alliance Management team and department, delivering alliance portfolio management and value for global partnerships in development and commercial life cycle phases. Prior to joining Jazz in 2019, Katherine was with Eli Lilly & Company and Elanco Animal Health, where she established and led the Alliance Management organization. For more than 20 years, Katherine has focused on global clinical development and strategic alliance partnering in the human and animal health pharmaceutical sector. She is passionate about building and optimizing alliance teams and advising alliance leaders, enabling challenging decision-making with a patient-focused, alliance value-driven approach. Katherine holds a BS in Biomedical Science from Texas A&M University and has been an active member of ASAP since 2011 holding a CSAP certification. It’s not all about work for Katherine-in her personal time, she is a veterinary nursing student at Purdue University and volunteers with the veterinary team for Save Elephant Foundation in Thailand, rescuing and rehabilitating endangered Asian Elephants.
Beatrice Lana, Strategic Alliance Executive, Cancer Research UK (CRUK)
Beatrice is a Strategic Alliance Executive at Cancer Research Horizons (CRH), the innovation and commercialization engine of Cancer Research UK, the world's largest charitable funder of cancer research. She joined the CRH team in 2018 to provide best-in-class alliance management to drive, support and expand CRUK’s innovative portfolio of strategic commercial alliances. Beatrice has played a key role in establishing, maintaining and progressing key alliances of the CHR portfolio, including the CRH-iOnctura alliance and currently the CRH-AstraZeneca Functional Genomic Centre alliance. Before that, Beatrice worked as Commercialisation Executive at Queen Mary Innovation, where she acquired expertise in opportunity sourcing and business development, leading on the translation of early-stage research projects into therapeutic, diagnostic and research development technologies.
Amanda McAllister, Director II, Global Alliance Leader, AbbVie
Amanda McAllister is a Global Alliance Leader at AbbVie with responsibility for AbbVie's collaborations with cross therapeutic platform technology, neurotoxins, and Allergan Aesthetics. She is an energetic and creative strategist, who inspires teams to move forward innovatively. She helps drive positive transformation by creating a collaborative and inclusive environment. Amanda has over 15 years of experience in pharma with roles spanning across supply chain, logistics, program management for all phases of drug development, commercialization, and alliance management. She’s passionate about challenging norms to make things better and, ultimately, changing people's lives in a positive and meaningful way.
Sharon Morgenbesser, Independent Alliance Management Consultant
Sharon is a senior level executive in the biotech/pharmaceutical industry and was most recently Executive Director, Alliance Management at Fulcrum Therapeutics. Sharon is currently providing Alliance Management support to Fulcrum as a part-time consultant to wind down a major alliance and provide support for another partnership. Prior to that, Sharon was Executive Director, Head of Alliance Management at AffaMed Therapeutics, where she managed 10 partnerships for 19 in-licensed assets, and established the Alliance Management function and Best Practices. Prior to joining AffaMed in 2021, Sharon was Director, Global Alliance Management at Sanofi for 4 and ½ years. Sharon has managed many Research, Development, and Commercial stage partnerships across a wide range of therapeutic areas, and with large pharmaceutical, small biotech, and digital therapeutics companies, with academic institutions, and for joint ventures. Sharon has spoken about her Alliance Management experiences at several Alliance Management and partnering conferences as a presenter and in panel discussions, and has also been interviewed for or written Alliance Management publications. Previously, Sharon held positions of increasing responsibility as a pre-clinical research scientist at Genzyme and Sanofi. During that time, Sharon led numerous project teams, focus groups, and External Innovation activities, and participated in, established, and managed several research collaborations. Sharon earned a B.S. in Molecular Genetics from the University of Rochester, a Ph.D. in Biology from the Albert Einstein College of Medicine, and CA-AM certification from the Association of Strategic Alliance Professionals (ASAP).
Beth Odeh-Frikert, PhD, Head SSF Global Alliance and Asset Management, Pharma Partnering, Genentech
Beth Odeh-Frikert is the Head of Global Alliance and Asset Management in Pharma Partnering at Genentech. Beth received her Doctorate of Pharmacy degree from the University of Michigan and completed a 2-year post-doctoral fellowship at Roche and Genentech, followed by an executive business program through INSEAD. During her 25-year career at Roche and Genentech, Beth has held key leadership positions across all phases of drug development and commercialization. Through her career, she has led global teams within Partnering, Product Development, Medical, Commercial and Manufacturing organizations. In her current role, Beth leads with a passion for science and a commitment to bring innovative medicines to patients through partnerships.
Traci Paciulli, Senior Director, Business Development Execution, Global Regulatory Affairs & Clinical Safety, Merck & Co.
Traci has over 28 years of cross functional experience at Merck & Co. Inc in the Global Finance, Marketing and Regulatory Affairs areas. She is a Six Sigma Blackbelt and experienced Change Management leader with a proven track record for implementing strategic change and standardizing operations to enable efficient execution activities in different parts of the business. Traci has established a consistent but flexible approach for all new deal execution of partnerships at Merck & Co., Inc. including collaborations, acquisitions and transitions for Global Regulatory Affairs and Clinical Safety.
Louis Rinfret, Founder & CEO, allianceboard
Combining his passions for alliance management and software Louis is on a mission to empower alliance teams to raise their influence and impact.
A longtime member of the Association of Strategic Alliance Professionals (ASAP), Louis has been active in managing, teaching about and researching strategic alliances for the past two decades. He is the founder and CEO of allianceboard, the strategic alliance management platform used by leading alliance management teams to consistently track alliance information, automate routine activities and leverage powerful insights to drive alliance success at scale.
Louis is an avid trail runner and when he is not at his desk you will probably find him training for the next race with his wife and two daughters.
Christopher Rodricks, Senior Director, Strategic Partnerships, Pfizer
Chris is a Strategic Partnerships Lead in Pfizer Ignite a new end-to-end developmental and clinical service model for biotech innovators to help advance novel therapies to market. In the past, Chris worked in Strategy and Consulting working across the R&D continuum from idea to launch and has been involved in and led a number of efforts across the drug development value chain from organizational redesign (e.g. creation of a new clinical organization, enabling functions), integration efforts (e.g. Wyeth, Allergan) and unit level strategies (e.g. GTx operations) to productivity analyses (e.g. productivity, metrics analyses, cost per POC), forecasting (e.g. pre-launch milestone forecasting) and competitive analyses linked to overall strategic priorities. Chris’s career is fueled by a relentless curiosity and a passion for forging meaningful connections with the extraordinary individuals he encounters. He is a proud alumnus of Stevens Institute of Technology, where he obtained a bachelor’s degree in Chemical Biology, and Rensselaer Polytechnic Institute, where he earned his MBA. Chris’s personal life is just as fulfilling as his professional one. He resides in Mystic, CT, with his wonderful wife, their spirited son, and two exuberant huskies, who bring joy and a touch of chaos to their home.
Diana Sanchez, PhD, Director, Alliance Management, Beam Therapeutics
Director of Alliance Management at Beam Therapeutics. Eight years of experience managing strategic alliances between academic partners, biotech companies and/or big pharma. Managed programs focused on diverse therapeutic areas (including metabolism, neuroscience, oncology and infectious disease, among others) and therapeutic modalities (base editing, gene therapy, antibodies and small molecules). Prior to Beam, worked for seven years at Harvard University most recently as Alliance Director, supporting alliances seeking to advance projects aligned with the pipeline interests of corporate alliance partners. Diana holds a PhD in Biomedical Engineering and is Certified in Alliance Management (CA-AM).
Christina Tan Hehir, Senior Director, Alliance Management, Orbital Therapeutics
Tina is currently Senior Director and Head of Alliance Management at Orbital Therapeutics, focused on applying Orbital’s platform to build a pipeline of innovative RNA medicines. In this role, she spearheads the company’s strategic alliances and participates in shaping new product planning and partnering strategy. In her previous role at Biogen, she managed a portfolio of drug development partnerships across a range of therapeutic modalities and stages. Earlier in her career at GE Global Research and GE Ventures, she led multiple programs and collaborations with pharma, biotech, academic, government, and VC partners. Tina holds a PhD in Chemistry from Boston College. She has a passion for driving innovation and optimizing the potential of partnerships to ensure mutual success to contribute to a mission of delivering life-changing medicines.
Peggy Taylor, Vice President, Head of Alliance Management, Alnylam
Peggy is Vice President and Head of Alliance Management at Alnylam where she leads a team responsible for ensuring the successful launch and execution of the company’s various partnerships in all stages of the drug development and commercialization lifecycle. She has over 20 years’ experience in the life science and biotech industry. Peggy holds an ScD in Cell Biology from Harvard University and started her career as a scientist. In subsequent roles, she developed broad leadership and business expertise, including experience in M&A. Prior to joining Alnylam in 2020, Peggy was the General Manager of the Neuroscience business unit at BioLegend.
Jan Twombly, CSAP, President, The Rhythm of Business
Jan Twombly, CSAP, is president of The Rhythm of Business, a consultancy and training firm with expertise in partnering, alliances, and collaboration. For over 20 years, she has been a leader in advancing the practice of alliance management. Current emphasis is on ensuring alliance professionals deliver the services of greatest value to stakeholders and digitizing its workflow. She serves on the Board of Directors of the Association of Strategic Alliance Professionals.
Grace Vandal, Executive Director, Alliance & Program Management, Zentalis Pharmaceuticals Inc.
Grace Vandal is Executive Director of Alliance and Program Management at Zentalis Pharmaceuticals, managing several clinical stage collaborations, as well as managing the Investigator Initiated Study program. Grace has over 25 years of experience in the biopharmaceutical industry. During her career at Pfizer, she managed drug development programs from preclinical through commercialization, leading to the successful registration of several marketed products. She also partnered with Business Development on collaborations, M&A and integrations. In 2020, Grace moved to Arvinas, a protein degrader company, to lead the clinical development of the estrogen and androgen receptor degrader programs and help to build out the clinical development organization. She is a certified Strategic Alliance Professional (ASAP) and certified Project Management Professional (PMI). She holds degrees in Chemistry, Quality Assurance/Regulatory Affairs and Business Administration. Grace is passionate about advancing novel, life changing, lifesaving, medicines to patients through collaboration and innovation.
Stefan Walke, Global Head of Alliance Management, Boehringer Ingelheim
Stefan, trained in biochemistry, has gained over 20 years of experience in the healthcare sector. His career spans consulting, biotech, and pharma, with a consistent emphasis on strategy and business development. In his tenure at Boehringer Ingelheim's Human Pharma Business Development organization, he initially led a combined Contracts & Alliance Management team before assuming the role of Global Head of Alliance Management. His team is dedicated to fostering preclinical and early clinical-stage alliances with innovation partners worldwide. These partnerships significantly contribute to the growth and diversification of Boehringer's R&D pipeline.
David Williams, Executive Director, GSK
I am an Alliance Director at GSK and have worked in the pharmaceutical industry for nearly 14 years. Prior to this, I spent nearly 10 years in the audit and compliance world at Ernst & Young and GSK. While my experiences as an auditor may not seem like a solid building block for Alliance Management, I believe it was exactly these experiences that molded my approach to effectively managing complex partnerships.
Doug Williams, Senior Director Alliance Management, Alliance Management, Incyte Corp.
With over 25 years of experience in Life Sciences, Doug specializes in cultivating strategic alliances within the Biotechnology and Pharmaceutical sectors. As an expert in driving innovation, maximizing value, and mitigating risk across diverse alliance portfolios, Doug has consistently delivered measurable results throughout his career. Known for fostering trust among diverse stakeholders, Doug's extensive collaboration experience spans the entire spectrum from research and development to commercialization. His proven track record in these areas underscores his dedication to advancing the field and achieving impactful outcomes. In addition to his expertise in life sciences, Doug has a growing interest in artificial intelligence. He is dedicated to building upon his foundation of knowledge in AI to further enhance strategic decision-making and optimize alliance management. His commitment to continuous learning reflects Doug's desire to be at the forefront of industry innovation.
Nisha Zaidi, PhD MSc, Vice President, Business Development, Head of Global Alliances, Bristol Myers Squibb
Nisha Zaidi is the Vice President, Head of Global Alliances in Business Development at Bristol Myers Squibb. With over 25 years in the biopharmaceutical industry, Nisha leads a team of strategic alliance leaders dedicated to building and optimizing partnerships that are essential for the long-term sustainability of the company’s pipeline. Nisha is committed to positioning Bristol Myers Squibb as the partner of choice by maximizing the value of its global strategic partnerships, leading small company integrations, and guiding alliance leaders to effectively drive decision-making throughout the life cycle of 300+ alliances. Nisha began her career as a protein biochemist at Sanofi, later transitioning into Global Medical Affairs to support launches in Sanofi’s Diabetes division. After joining Celgene in 2014, she led multiple drug launches within US Medical Affairs, before moving into Global Alliance leadership. Nisha holds a BSc from Rutgers University and both an MSc and PhD from the University of Medicine and Dentistry of New Jersey.
